Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 3.7% year on year to $330.6 million. Its non-GAAP profit of $1.24 per share was 1.6% above analysts’ consensus estimates. Is now the time to buy Haemonetics? Find out in our full research report. Haemonetics (HAE) Q1 CY2025 Highlights: Revenue: $330.6 million vs analyst estimates of $327.3 million (3.7% year-on-year decline, 1% beat) Adjusted EPS: $1.24 vs analyst estimates of $1.22 (1.6% beat) Adjusted EBITDA: $106.5 million vs analyst estimates of $105.8 million (32.2% margin, 0.6% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $4.85 at the midpoint, missing analyst estimates by 1.6% Operating Margin: 21.6%, up from 8.7% in the same quarter last year Free Cash Flow was -$70.83 million, down from $29.23 million in the same quarter last year Organic Revenue was flat year on year (10.2% in the same quarter last year) Market Capitalization: $3.23 billion Company Overview With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE:HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals. Sales Growth A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Regrettably, Haemonetics’s sales grew at a mediocre 6.6% compounded annual growth rate over the last five years. This fell short of our benchmark for the healthcare sector and is a poor baseline for our analysis.Haemonetics Quarterly Revenue We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Haemonetics’s annualized revenue growth of 7.9% over the last two years is above its five-year trend, suggesting some bright spots.Haemonetics Year-On-Year Revenue Growth Haemonetics also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Haemonetics’s organic revenue averaged 6.8% year-on-year growth. Because this number aligns with its normal revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results.Haemonetics Organic Revenue Growth This quarter, Haemonetics’s revenue fell by 3.7% year on year to $330.6 million but beat Wall Street’s estimates by 1%. Looking ahead, sell-side analysts expect revenue to decline by 2.5% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will face some demand challenges. Story Continues Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Haemonetics has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 12.5%, higher than the broader healthcare sector. Looking at the trend in its profitability, Haemonetics’s operating margin rose by 6 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 2.9 percentage points on a two-year basis.Haemonetics Trailing 12-Month Operating Margin (GAAP) In Q1, Haemonetics generated an operating profit margin of 21.6%, up 12.9 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Haemonetics’s decent 6.7% annual EPS growth over the last five years aligns with its revenue performance. This tells us its incremental sales were profitable.Haemonetics Trailing 12-Month EPS (Non-GAAP) In Q1, Haemonetics reported EPS at $1.24, up from $0.90 in the same quarter last year. This print beat analysts’ estimates by 1.6%. Over the next 12 months, Wall Street expects Haemonetics’s full-year EPS of $4.57 to grow 8.1%. Key Takeaways from Haemonetics’s Q1 Results We were impressed by how significantly Haemonetics blew past analysts’ organic revenue expectations this quarter. We were also happy its revenue narrowly outperformed Wall Street’s estimates. On the other hand, its full-year EPS guidance missed. Overall, this print had some key positives. The stock traded up 2.4% to $65.79 immediately following the results. Is Haemonetics an attractive investment opportunity at the current price? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free. View Comments
Haemonetics (NYSE:HAE) Surprises With Q1 Sales
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...